Deferiprone is an iron chelator medication used to treat thalassemia major. Suppliers of deferiprone market it in the form of 500mg and 1000mg oral tablets. The developer and earliest manufacturer of deferiprone is Apotex Pharmaceuticals, which first introduced the drug into the market in 1994. It is currently approved in over 60 countries worldwide, including but not limited to China, Australia, the U.S., and across Europe. Apotex remains the largest manufacturer and supplier of deferiprone medications globally. Retail prices per 100 (500mg) tablets of deferiprone are typically around 300 EUR.